For the quarter ending 2025-09-30, ACTU made $5,542,349 in revenue. -$5,407,470 in net income. Net profit margin of -97.57%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 2,177,922 | 2,764,805 | ||
| General and administrative | 3,294,456 | 3,204,072 | ||
| Total operating expenses | 5,472,378 | 5,968,877 | ||
| Loss from operations | -5,472,378 | -5,968,877 | ||
| Change in estimated fair value of warrant liability | 0 | 0 | ||
| Gain on settlement of warrants | 0 | - | ||
| Loss on issuance of related party convertible notes payable at fair value | 0 | 0 | ||
| Change in estimated fair value of related party convertible notes payable | 0 | 0 | ||
| Interest expense | 5,063 | 5,062 | ||
| Interest income | 69,971 | 24,534 | ||
| Total other income (expense), net | 64,908 | 19,472 | ||
| Net loss | -5,407,470 | -5,949,405 | ||
| Net loss per share attributable to common stockholders, basic | -0.25 | -0.3 | ||
| Net loss per share attributable to common stockholders, diluted | -0.25 | -0.3 | ||
| Weighted-average shares of common stock outstanding, basic | 21,394,965 | 19,646,475 | ||
| Weighted-average shares of common stock outstanding, diluted | 21,394,965 | 19,646,475 | ||
ACTUATE THERAPEUTICS, INC. (ACTU)
ACTUATE THERAPEUTICS, INC. (ACTU)